secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001213900-25-032565
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio receives favorable USPTO patentability opinion for CORDStrom platform
--------------------------------------------------------------------------------

- USPTO, as International Search Authority, issued favorable opinion on all claims of PCT/US25/17028 on April 8, 2025.
- Opinion confirms novelty, inventive step, and industrial applicability for CORDStrom pooled hucMSC therapy.
- Patent, once granted, would provide IP exclusivity for CORDStrom through at least 2045, subject to extensions.
- Company plans to accelerate U.S. national application via Patent Prosecution Highway (PPH) fast-track program.
- Follows recent Phase 2 trial data showing CORDStrom reduced pain and itch with early skin integrity signals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025032565/0001213900-25-032565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025032565/ea0238598-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer